Elocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). It contains the active substance efmoroctocog alfa.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Elocta can be used for all age groups.
Therapeutic Area (MeSH)
N/AATC Code
B02BD02
ATC Item
coagulation factor VIII
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| efmoroctocog alfa | N/A | Efmoroctocog alfa |
EMA Name
Elocta
Medicine Name
Elocta
Aliases
N/ANo risk management plan link.
